Recruiting
Trop2-targeted immunoPET Imaging of Solid Tumors
NCT06851663
Adenocarcinoma, Adnexal Diseases
Shanghai, China
View Trial Details
Not Yet Recruiting
NCT Number: NCT06663735
Current Status of Diagnosis and Treatment of Uroepithelial Carcinoma
A cross-sectional study describing the current status of diagnosis and treatment of uroepithelial cancer in hospitals of different grades in Henan Province
Not Yet Recruiting
Trial opening soon.
Get NotifiedKey information
Conditions
Age range
18 year–75 year
Sex eligibility
All sexes
Study type
Observational
Primary location
Kaifeng City Center Hospital, Kaifeng, Henan, China
Loading trial locations.
About this study
Patients diagnosed with uroepithelial carcinoma attending multiple research center hospitals in Henan Province from January 1, 2023 to December 31, 2023 A questionnaire was used to collect and analyze the treatment patterns of patients with early versus advanced uroepithelial cancer in different levels of hospitals in Henan Province.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Adults ≥18 years of age (at enrollment)
- Histologically confirmed uroepithelial carcinoma
- Patients with newly diagnosed or completed radical uroepithelial carcinoma in the early stages of uroepithelial cancer/advanced unresectable or with distant metastases of urothelial carcinoma
- Complete medical history information
Exclusion criteria
- Incomplete medical history and medical records
Treatment and study plan
Primary outcomes
-
Describing the diagnosis and treatment patterns of patients with early versus advanced uroepithelial carcinoma in different grades of hospitals in Henan Province
Time frame: up to the patients enrolled,an average of 1 year
To describe the similarities and differences between the way patients with early and advanced uroepithelial cancer are diagnosed and treated in different levels of hospitals in Henan Province and the current guidelines for uroepithelial cancer.
Secondary outcomes
-
Comparison of differences in diagnosis and treatment patterns between patients with early-stage and advanced uroepithelial carcinoma in county hospitals and different consultation departments of the same hospital in Henan province
Time frame: up to the patients enrolled,an average of 1 year
The main purpose of this study is to compare the differences between the diagnosis and treatment modalities and guidelines for early and advanced uroepithelial cancer patients in Henan Province in county hospitals. It also compares the differences in treatment modalities between different departments in the same level of hospitals.
-
Describing the pathology as well as genetic testing of patients with uroepithelial carcinoma in different grades of hospitals in Henan province
Time frame: up to the patients enrolled,an average of 1 year
- Proportion of different genes/proteins tested in patients with uroepithelial cancer (mutations in FGFR, HER2, HRR, ARID1A and CREBBP, TP53, CDKN2A and PD-L1 expression)
- Proportion of early and advanced uroepithelial cancer patients with high expression/mutations of different genes and use of targeted therapies
Study contacts
Contact information is provided by the study sponsor or research team.
Sponsors and collaborators
Lead sponsor
The First Affiliated Hospital of Xinxiang Medical College
Other
Registry information
Official study title
A Cross-sectional Study Describing the Current Status of Diagnosis and Treatment of Uroepithelial Cancer in Hospitals of Different Grades in Henan Province
Important dates
- Study start
- 2024
- Primary completion
- 2025
- Study completion
- 2025
- First posted
- Oct 29, 2024
- Registry last updated
- Oct 29, 2024
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Not Yet Recruiting
Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC
NCT07671092
Breast Cancer, Breast Diseases
Christchurch, New Zealand
View Trial Details
Not Yet Recruiting
FAPI PET Imaging - An Exploratory Study
NCT07705074
Adenocarcinoma, Adenoma
Baden, Canton of Aargau, Switzerland
View Trial Details
Not Yet Recruiting
Sacituzumab Tirumotecan vs MMAE-ADCs in Advanced Urothelial Carcinoma (FUSCC-SPARE-UC-01)
NCT07662863
Bladder Cancer, Carcinoma
Shanghai, Shanghai Municipality, China
View Trial Details